| Elizabeth Seidl, PT, DPT | |
|
3801 Lake Otis Pkwy Ste 300, Anchorage, AK 99508 | |
| (907) 562-2277 | |
| (907) 563-3460 |
| Full Name | Elizabeth Seidl |
|---|---|
| Gender | Female |
| Speciality | Physical Therapy |
| Experience | 8 Years |
| Location | 3801 Lake Otis Pkwy Ste 300, Anchorage, Alaska |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225570864 | NPI | - | NPPES |
| 1657641 | Medicaid | AK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2251X0800X | Physical Therapist - Orthopedic | 113303 (Alaska) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Orthoalaska Llc | 2961705520 | 125 |
News Archive
Jazz Pharmaceuticals plc announced today that the first patients have been enrolled in a Phase 3 clinical development program evaluating the safety and efficacy of its investigational drug candidate, JZP-110, as a wake-promoting agent in the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy or with obstructive sleep apnea (OSA).
Many children are being put at risk by parents over-use of widely available over the counter (OTC) medicines for fever, coughs and colds, says a study from Australia to be presented to the annual conference of the International Pharmaceutical Federation (FIP) today (Monday 30 August).
A new study by a team of researchers led by Jeffrey Peng, assistant professor of chemistry and biochemistry at the University of Notre Dame, is using Nuclear Magnetic Resonance, to move drug design into groundbreaking consideration of the dynamic flexibility of drugs and their targets.
Juventas Therapeutics, a clinical-stage regenerative medicine company developing novel therapies for cardiovascular disease, announces that the U.S. Food and Drug Administration (FDA) authorized commencement of a Phase II clinical trial evaluating the efficacy and safety of its lead product, JVS-100, for the treatment of critical limb ischemia (CLI).
The cost of low health literacy - the difference between patients' abilities to understand health information and providers' abilities to effectively communicate complex medical information - is $106 billion to $238 billion annually, according to Pfizer, a leading biopharmaceutical company. To improve the health literacy of professionals and patients, the University of Missouri will offer a health literacy study emphasis beginning this fall.
› Verified 6 days ago
| Provider Name | Orthoalaska Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1336504521 PECOS PAC ID: 2961705520 Enrollment ID: O20160114002729 |
News Archive
Jazz Pharmaceuticals plc announced today that the first patients have been enrolled in a Phase 3 clinical development program evaluating the safety and efficacy of its investigational drug candidate, JZP-110, as a wake-promoting agent in the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy or with obstructive sleep apnea (OSA).
Many children are being put at risk by parents over-use of widely available over the counter (OTC) medicines for fever, coughs and colds, says a study from Australia to be presented to the annual conference of the International Pharmaceutical Federation (FIP) today (Monday 30 August).
A new study by a team of researchers led by Jeffrey Peng, assistant professor of chemistry and biochemistry at the University of Notre Dame, is using Nuclear Magnetic Resonance, to move drug design into groundbreaking consideration of the dynamic flexibility of drugs and their targets.
Juventas Therapeutics, a clinical-stage regenerative medicine company developing novel therapies for cardiovascular disease, announces that the U.S. Food and Drug Administration (FDA) authorized commencement of a Phase II clinical trial evaluating the efficacy and safety of its lead product, JVS-100, for the treatment of critical limb ischemia (CLI).
The cost of low health literacy - the difference between patients' abilities to understand health information and providers' abilities to effectively communicate complex medical information - is $106 billion to $238 billion annually, according to Pfizer, a leading biopharmaceutical company. To improve the health literacy of professionals and patients, the University of Missouri will offer a health literacy study emphasis beginning this fall.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Elizabeth Seidl, PT, DPT 3801 Lake Otis Pkwy Ste 300, Anchorage, AK 99508-5234 Ph: (907) 562-2277 | Elizabeth Seidl, PT, DPT 3801 Lake Otis Pkwy Ste 300, Anchorage, AK 99508 Ph: (907) 562-2277 |
News Archive
Jazz Pharmaceuticals plc announced today that the first patients have been enrolled in a Phase 3 clinical development program evaluating the safety and efficacy of its investigational drug candidate, JZP-110, as a wake-promoting agent in the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy or with obstructive sleep apnea (OSA).
Many children are being put at risk by parents over-use of widely available over the counter (OTC) medicines for fever, coughs and colds, says a study from Australia to be presented to the annual conference of the International Pharmaceutical Federation (FIP) today (Monday 30 August).
A new study by a team of researchers led by Jeffrey Peng, assistant professor of chemistry and biochemistry at the University of Notre Dame, is using Nuclear Magnetic Resonance, to move drug design into groundbreaking consideration of the dynamic flexibility of drugs and their targets.
Juventas Therapeutics, a clinical-stage regenerative medicine company developing novel therapies for cardiovascular disease, announces that the U.S. Food and Drug Administration (FDA) authorized commencement of a Phase II clinical trial evaluating the efficacy and safety of its lead product, JVS-100, for the treatment of critical limb ischemia (CLI).
The cost of low health literacy - the difference between patients' abilities to understand health information and providers' abilities to effectively communicate complex medical information - is $106 billion to $238 billion annually, according to Pfizer, a leading biopharmaceutical company. To improve the health literacy of professionals and patients, the University of Missouri will offer a health literacy study emphasis beginning this fall.
› Verified 6 days ago
Katrina F Johnson, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 4315 Diplomacy Dr, Anchorage, AK 99508 Phone: 907-563-2662 | |
Jessie Lief, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 4031 Winchester Loop, Anchorage, AK 99507 Phone: 907-244-8048 | |
Zoe Anneliese Morris Nelson, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1917 Abbott Rd Ste 200, Anchorage, AK 99507 Phone: 907-279-4266 | |
Normajean Farr, PT Physical Therapist Medicare: Medicare Enrolled Practice Location: 2221 E Northern Lights Blvd, Suite 106, Anchorage, AK 99508 Phone: 907-677-5605 | |
Mary Beth Nearing, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 602 W 42nd Ave, Anchorage, AK 99503 Phone: 907-360-9448 Fax: 907-346-1470 | |
Kids Are People Too Llc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 6311 Debarr Rd, Suite J, Anchorage, AK 99504 Phone: 907-830-3592 Fax: 907-338-4691 | |
Ms. Catherine A Coward, MSPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 9500 Independence Dr, Ste 900, Anchorage, AK 99507 Phone: 907-522-1341 Fax: 907-522-1343 |